Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
05 Setembro 2023 - 9:05AM
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare
company, today announced that Chairperson and Chief Executive
Officer Al Altomari and Chief Commercial Officer Amy Welsh will
present at the H.C. Wainwright 25th Annual Global Investment
Conference taking place September 11-13, 2023 in New York, NY.
Details on the Company presentation are as
follows:
Event: H.C. Wainwright 25th Annual Global
Investment Conference
Date: Wednesday, September 13, 2023
Time: 12:30-1:00 pm ET
Webcast:
https://journey.ct.events/view/e4e66bfd-32ea-4cee-8886-e55b6dfc3b2a
The presentation webcast will also be available
on the Investor Relations page of the Company’s website at
https://ir.agiletherapeutics.com/events-and-presentations. The
replay of the webcast will be archived on the website for 30 days
after the presentation.
About Agile
Therapeutics, Inc.Agile
Therapeutics is a women's healthcare company dedicated to
fulfilling the unmet health needs of today’s women. Our product and
product candidates are designed to provide women with contraceptive
options that offer freedom from taking a daily pill, without
committing to a longer-acting method. Our initial product, Twirla®,
(levonorgestrel and ethinyl estradiol) transdermal system is a
non-daily prescription contraceptive. Twirla is based on our
proprietary transdermal patch technology, called Skinfusion®, which
is designed to allow drug delivery through the skin. For more
information, please visit the company website at
www.agiletherapeutics.com. The Company may
occasionally disseminate material, nonpublic information on the
Company’s website, Twitter account (@agilether), and LinkedIn
account.
Contact:Matt RileyHead of Investor Relations
& Corporate Communicationsmriley@agiletherapeutics.com
Agile Therapeutics (NASDAQ:AGRX)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Agile Therapeutics (NASDAQ:AGRX)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024